Drug Price Trends for PYRIDOSTIGMINE ER

Average Pharmacy Cost for PYRIDOSTIGMINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
PYRIDOSTIGMINE ER 180 MG TAB	47781-0335-30	4.83041	EACH	2025-03-19
PYRIDOSTIGMINE ER 180 MG TAB	68682-0301-30	4.83041	EACH	2025-03-19
PYRIDOSTIGMINE ER 180 MG TAB	64980-0220-03	4.83041	EACH	2025-03-19
PYRIDOSTIGMINE ER 180 MG TAB	00115-1404-08	4.83041	EACH	2025-03-19
PYRIDOSTIGMINE ER 180 MG TAB	47781-0335-30	5.59584	EACH	2025-02-19

Market Analysis and Price Projections for Pyridostigmine ER

Introduction to Pyridostigmine ER

Pyridostigmine, a cholinergic muscle stimulant, is widely used for treating conditions such as myasthenia gravis, dysautonomia, and as a pretreatment for nerve agent exposure. The extended-release (ER) formulation of pyridostigmine, recently approved by the FDA, offers a once-daily dosing option, enhancing patient compliance and convenience[4].

Market Overview

The global market for pyridostigmine, including its ER formulation, is driven by several factors:

Increasing Demand

The demand for pyridostigmine is increasing due to its versatile applications, including the treatment of myasthenia gravis and other neuromuscular disorders. The U.S. Armed Services and its allies also utilize pyridostigmine as a pretreatment for soman nerve agent exposure, contributing to the market demand[4].

Technological Advancements

The development of extended-release formulations, such as Amneal’s Pyridostigmine Bromide Extended-Release (PB ER) Tablets, using advanced drug delivery technologies like GRANDE, is a significant market driver. These innovations improve the efficacy and convenience of the medication, attracting more patients and healthcare providers[4].

Generic and Brand Competition

The market for pyridostigmine includes both generic and brand-name products. Generic versions, such as those available from various manufacturers, offer competitive pricing, while brand-name products like Mestinon Timespan maintain a strong market presence due to their established reputation and quality[2][5].

Pricing Analysis

Current Pricing

The prices for pyridostigmine ER vary based on the formulation and quantity:

• Pyridostigmine ER 180 mg Tablets: The cost for a supply of 30 tablets can range from $309.96, with a per-unit price of approximately $10.33[2].
• Pyridostigmine Bromide Extended-Release (PB ER) Tablets: Although specific pricing for Amneal’s newly approved PB ER is not yet widely available, it is expected to be competitive with existing ER formulations[4].

Oral Syrup vs. Tablets

For comparison, the oral syrup formulation of pyridostigmine (60 mg/5 mL) can cost around $279.80 for 50 milliliters, while the extended-release tablets offer a more convenient dosing schedule[2][5].

Price Projections

Market Trends

The global pyridostigmine bromide API market is anticipated to grow significantly over the next few years. The market was valued at several million USD in 2023 and is expected to reach higher values by 2030, driven by increasing demand and technological advancements[3].

Regional Variations

Price projections vary by region due to differences in production costs, regulatory environments, and market demand. For instance, North America and Europe are expected to see steady growth in the production value of pyridostigmine bromide API, while Asia Pacific regions may experience higher growth rates due to expanding healthcare infrastructure[3].

Impact of FDA Approval

The recent FDA approval of Amneal’s Pyridostigmine Bromide Extended-Release Tablets is expected to influence pricing by introducing a new, innovative product into the market. This could lead to competitive pricing adjustments among existing products to maintain market share[4].

Competitive Landscape

The market for pyridostigmine ER is competitive, with several key players:

• Amneal Pharmaceuticals: With the recent FDA approval of their PB ER tablets, Amneal is poised to capture a significant share of the market[4].
• Generic Manufacturers: Companies like Golden State Medical Supply and ANI Pharmaceuticals offer generic versions of pyridostigmine, providing cost-effective alternatives[1][2].
• Brand-Name Products: Mestinon and Mestinon Timespan, brand-name versions of pyridostigmine, continue to hold a strong market presence due to their established quality and reputation[2][5].

Consumer and Patient Impact

Cost Savings

The availability of generic and extended-release formulations can lead to cost savings for patients. For example, using a discount card can reduce the cost of pyridostigmine tablets significantly, making the medication more accessible[2].

Improved Compliance

The once-daily dosing of pyridostigmine ER formulations enhances patient compliance, which can lead to better health outcomes and reduced healthcare costs in the long term[4].

Adverse Reactions and Safety Considerations

While pyridostigmine ER offers several benefits, it is important to consider the potential adverse reactions. Common serious adverse reactions include breathing difficulties, dizziness, and loss of consciousness. Other reported adverse reactions include dysmenorrhea, nosebleeds, reduced vision in one eye, and decreased tactile sensitivity[4].

Key Takeaways

• Increasing Demand: The market for pyridostigmine ER is driven by increasing demand for treatments of myasthenia gravis and other conditions.
• Technological Advancements: Extended-release formulations enhance patient compliance and convenience.
• Competitive Pricing: Generic and brand-name products compete in the market, with prices varying based on formulation and quantity.
• Regional Growth: The global market is expected to grow, with regional variations in production value and demand.
• Patient Impact: Cost savings and improved compliance are significant benefits for patients.

FAQs

1. What is Pyridostigmine ER used for? Pyridostigmine ER is used for treating conditions such as myasthenia gravis, dysautonomia, and as a pretreatment for nerve agent exposure.

2. How does the extended-release formulation benefit patients? The extended-release formulation allows for once-daily dosing, enhancing patient compliance and convenience.

3. What are the common adverse reactions to Pyridostigmine ER? Common serious adverse reactions include breathing difficulties, dizziness, and loss of consciousness. Other reported adverse reactions include dysmenorrhea, nosebleeds, reduced vision in one eye, and decreased tactile sensitivity.

4. How does the pricing of Pyridostigmine ER compare to other formulations? The pricing of Pyridostigmine ER is competitive with other formulations, with costs ranging from $309.96 for a supply of 30 tablets, depending on the manufacturer and pharmacy.

5. What is the expected market growth for Pyridostigmine Bromide API? The global Pyridostigmine Bromide API market is anticipated to grow significantly over the next few years, driven by increasing demand and technological advancements.

Sources

1. DrugPatentWatch: Drug prices and trends for PYRIDOSTIGMINE.
2. Drugs.com: Pyridostigmine Prices, Coupons, Copay Cards & Patient Assistance.
3. QYResearch: Global Pyridostigmine Bromide API Market Research Report 2024.
4. Amneal Pharmaceuticals: Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended Release Tablets.
5. Drugs.com: Mestinon Prices, Coupons, Copay Cards & Patient Assistance.